Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki Disease.
Antirheumatic Agents
/ adverse effects
Biomarkers
Child, Preschool
Computed Tomography Angiography
Demyelinating Diseases
/ diagnosis
Female
Follow-Up Studies
Humans
Immunoglobulins, Intravenous
/ administration & dosage
Infant
Infliximab
/ adverse effects
Magnetic Resonance Imaging
Male
Mucocutaneous Lymph Node Syndrome
/ complications
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
21
5
2019
medline:
28
4
2020
entrez:
21
5
2019
Statut:
ppublish
Résumé
We performed brain magnetic resonance imaging in 14 patients with Kawasaki disease who were treated with infliximab (IFX) at 56 months of age (32-62 months of age) and 23 months (5-35 months) after IFX therapy. Magnetic resonance imaging showed no finding of the central nervous demyelination. IFX therapy is not related to central nervous demyelination in patients with Kawasaki disease.
Identifiants
pubmed: 31107420
doi: 10.1097/INF.0000000000002296
doi:
Substances chimiques
Antirheumatic Agents
0
Biomarkers
0
Immunoglobulins, Intravenous
0
Tumor Necrosis Factor-alpha
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM